Breakthrough British machine-learning biotech firm strikes deal to develop new cancer treatments

Breakthrough British machine-learning biotech firm strikes deal to develop new cancer treatments

Etcembly, a breakthrough biotech company that uses machine learning to identify and predict the effectiveness of future immune therapies, has partnered with Norway’s leading company Zelluna to design T cell receptors (TCRs) from Zelluna’s pipeline against an undisclosed cancer target.

The commercial agreement will involve Etcembly designing Zelluna’s TCR candidates and Zelluna developing them further through full preclinical evaluations and beyond in development.

The Oxford-based company will incorporate “hundreds of millions of data points” to rigorously test molecular adaptations in a quarter of the time it typically takes using traditional methods.

It is hoped that the agreement will help in the development of future treatments for a variety of cancers.

Etcembly CEO Dr Michelle Teng said the deal could be a major turning point for the discovery of new immunotherapies against the disease.

“This partnership agreement with Zelluna represents a huge step forward for the research and development of new cancer treatments,” she said.

“Our goal is to significantly reduce preclinical lead times and provide strong validation for clinical candidates by providing evidence for the efficacy and safety of TCR.

“We very much look forward to working with Zelluna to help accelerate preclinical research in the race to find new cancer treatments.”

The deal will involve Etcembly testing and optimizing Zelluna TCR candidates over the next 12 months.

The Norwegian company hopes that this decision will help develop optimized TCR-guided natural killer cell therapies for several solid cancers.

As one of the only companies in the world to incorporate machine learning into its molecular testing, Dr. Teng added that Etcembly’s approach of combining machine learning and gene therapy could save the company money. pharmaceutical industry “years of testing and millions of pounds”.

Dr. Teng also believes the deal with Zelluna could help accelerate the wider adoption of machine learning technologies across the industry.

“The benefits are too great to ignore,” she said. “The latest technologies, combined with the data points we now have, make it an invaluable tool for rapidly accelerating the development of new therapies.

“As machine learning gains momentum, it will undoubtedly become a staple for pharmaceutical companies in the future.

“We are already pushing the boundaries to explore the intersection between immunology and machine learning, which has the potential to transform the industry in the years to come.”

For more information visit www.etcembly.com

Sherry J. Basler